48.1 Palpable Breast Mass, Mastitis & Nipple Discharge

Diagnostic Approach to a Palpable Breast Mass

A palpable breast mass is one of the most common and anxiety-provoking chief complaints encountered in family medicine. While the vast majority (>80% to 90%) of palpable breast masses in premenopausal women represent benign pathology (such as fibrocystic changes, fibroadenomas, or simple cysts), the primary clinical objective is the rapid, definitive exclusion of invasive breast malignancy. Every palpable dominant mass demands systematic diagnostic evaluation regardless of recent normal screening mammography results.

The Age-Stratified Imaging Algorithm

Breast tissue composition changes substantially across the female lifespan. Young women possess dense fibrous and glandular connective tissue, whereas postmenopausal women undergo gradual involution where radiodense parenchyma is replaced by radiolucent adipose tissue. Consequently, the initial imaging modality of choice is strictly stratified by patient age:

               AGE-STRATIFIED IMAGING FOR A PALPABLE BREAST MASS

   Patient Age Category       Initial Imaging Modality         Clinical Rationale
   ═══════════════════════════════════════════════════════════════════════════════════════════════
   Women Aged < 30 Years      Targeted Breast Ultrasound       Dense fibroglandular tissue produces
                              (Initial Diagnostic Modality)    mammographic obscuration (false negatives);
                                                               ultrasound differentiates cystic from
                                                               solid masses with exceptional sensitivity.

   Women Aged >= 30 Years     Diagnostic Mammography           Bilateral diagnostic mammogram (spot
                              PLUS Targeted Breast Ultrasound  compression/magnification) assesses micro-
                              (Combined Modality)              calcifications, architectural distortion, and
                                                               occult multifocal disease; ultrasound
                                                               characterizes the palpable focal index lesion.
   ═══════════════════════════════════════════════════════════════════════════════════════════════

1. Women Aged < 30 Years (Targeted Ultrasound First)

• In women younger than 30 years (and pregnant or lactating women of any age), ionizing radiation should be minimized, and dense breast tissue renders conventional mammography insensitive.
• Targeted Breast Ultrasound is the initial diagnostic test of choice. It immediately answers the critical clinical question: Is the palpable mass cystic or solid?
  • Simple Cyst: Demonstrates anechoic lumen, smooth thin margins, round or oval shape, and posterior acoustic enhancement with no internal vascularity or wall nodularity. Simple cysts are entirely benign (BI-RADS 2). Management is reassurance; therapeutic aspiration is indicated only if the cyst is painful, tensely distended, or symptomatic.
  • Complicated Cyst: Contains low-level internal echoes or fluid-debris levels without thick walls or vascularity (BI-RADS 3). Follow with repeat ultrasound in 6 months or perform fine-needle evacuation.
  • Complex Solid-Cystic or Solid Mass: Displays internal hypoechoic solid tissue, thick irregular septations, or vascularity. This requires diagnostic bilateral mammography followed by image-guided Core Needle Biopsy (CNB).

2. Women Aged >= 30 Years (Diagnostic Mammogram + Targeted Ultrasound)

• In women aged 30 and older, initial evaluation requires a Diagnostic Mammogram accompanied by Targeted Breast Ultrasound.
• Diagnostic vs. Screening Mammography:
  • A screening mammogram is a standard 2-view study (craniocaudal [CC] and mediolateral oblique [MLO]) performed on asymptomatic individuals.
  • A diagnostic mammogram is an individualized, problem-focused study performed with an on-site radiologist. It includes specialized views: spot compression (displaces overlapping glandular parenchyma to verify a true lesion) and magnification views (evaluates pleomorphic microcalcifications and fine spiculation).
  • Mammography evaluates both breasts to detect non-palpable multicentric or contralateral synchronous lesions.
  • Targeted ultrasound is simultaneously performed over the palpable abnormality to determine internal echo texture and margins.

The "Triple Assessment" & The Superiority of Core Needle Biopsy

The diagnostic safety net for breast lump evaluation is the internationally validated Triple Assessment. When all three components are concordant, the diagnostic accuracy exceeds 99%.

The Three Components of the Triple Assessment

1. Clinical Breast Examination (CBE): Precise localization, size measurement, mobility, skin dimpling, nipple retraction, chest wall fixation, and regional lymph node staging (axillary, supraclavicular, infraclavicular).
2. Diagnostic Breast Imaging: Age-appropriate imaging (diagnostic mammography and/or targeted ultrasound) culminating in a standardized Breast Imaging Reporting and Data System (BI-RADS) category.
3. Tissue Histopathology: Percutaneous image-guided tissue sampling.

                    THE TRIPLE ASSESSMENT CONCORDANCE MATRIX

   Component                  Benign Profile                     Malignant Profile
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Clinical Exam              Smooth, soft/rubbery, mobile,      Hard, irregular margins, fixed,
                              non-tender, no skin tethering      skin dimpling, nipple retraction

   Diagnostic Imaging         Circumscribed oval mass,           Spiculated, taller-than-wide, micro-
   (Mammogram / Ultrasound)   anechoic cyst, BI-RADS 2 or 3      calcifications, shadowing, BI-RADS 4/5

   Tissue Biopsy              Fibroadenoma, fibrocystic tissue,  Invasive ductal carcinoma, DCIS,
   (Core Needle Biopsy)       stromal fibrosis                   invasive lobular carcinoma
   ═════════════════════════════════════════════════════════════════════════════════════════════
   RULE OF DISCORDANCE: If ANY ONE of the three components is suspicious or discordant with
   the others, surgical excision or re-biopsy is MANDATORY to rule out occult carcinoma.

Why Core Needle Biopsy (CNB) is the Gold Standard over FNA

Historically, Fine Needle Aspiration (FNA) was widely used for breast lumps. Today, image-guided (ultrasound- or stereotactic-guided) Core Needle Biopsy (CNB) is the unquestioned standard of care. Family physicians must recognize why FNA is no longer sufficient for suspicious solid lesions:

• Tissue Architecture Preservation: CNB extracts intact cores of tissue (using a 14-gauge spring-loaded cutting needle), preserving the histologic relationship between epithelial cells, the basement membrane, and the surrounding stroma.
• Differentiating DCIS from Invasive Carcinoma:
  • FNA provides only single-cell cytologic smears without architecture. Cytology can confirm the presence of malignant epithelial cells, but FNA CANNOT determine whether tumor cells have broken through the basement membrane.
  • CNB directly visualizes the basement membrane, decisively distinguishing non-invasive Ductal Carcinoma In Situ (DCIS) from Invasive Ductal Carcinoma (IDC). This distinction fundamentally alters surgical staging (e.g., determining the necessity of sentinel lymph node biopsy).
• Biomarker and Receptor Profiling: CNB supplies sufficient tissue volume to perform immunohistochemical staining and fluorescence in situ hybridization (FISH) for therapeutic biomarkers: Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Ki-67 proliferation index. Neoadjuvant chemotherapy and endocrine therapy decisions depend completely on these receptors.
• Low Non-Diagnostic Rate: CNB has an insufficient sampling rate of <2%, compared to up to 15% to 20% for FNA.

Common Benign Breast Masses

1. Fibroadenoma

• Epidemiology: The most common solid benign breast neoplasm in adolescent girls and young women (peak incidence between ages 15 and 35 years).
• Pathophysiology: A benign fibroepithelial proliferation arising from the terminal duct lobular unit (TDLU). The stromal component responds to circulating ovarian sex hormones.
• Clinical Presentation: A solitary, well-circumscribed, firm, rubbery, smoothly bordered, non-tender, highly mobile ("breast mouse") mass. Size typically ranges from 1 to 3 cm. The mass frequently enlarges during periods of estrogen stimulation (pregnancy, menses, oral contraceptive initiation) and undergoes hyalinization, calcification, and involution after menopause.
• Imaging Characteristics: Ultrasound demonstrates an oval, circumscribed, hypoechoic or isoechoic mass with a horizontal orientation ("wider than tall"), thin echogenic pseudocapsule, and uniform internal echogenicity (BI-RADS 2 or 3).
• Clinical Management:
  • In women <25 years with classic imaging, conservative observation with clinical exam and repeat ultrasound in 6 months is safe.
  • Core needle biopsy is indicated if the lesion is >=2 to 3 cm, exhibits atypical imaging features, is rapidly enlarging, or if the patient desires definitive confirmation.
  • Surgical excision is reserved for giant fibroadenomas (>5 cm), persistent pain, or suspicion of a phyllodes tumor.

2. Fibrocystic Changes

• Epidemiology: The most common benign condition of the breast overall, affecting up to 50% to 60% of premenopausal women aged 20 to 50 years.
• Pathophysiology: An exaggerated physiologic tissue response to cyclical fluctuations of estrogen and progesterone, characterized by glandular ductal dilation (micro- and macrocysts), stromal fibrosis, and apocrine metaplasia.
• Clinical Presentation: Bilateral, diffuse, fluctuating breast nodularity (frequently described as a "cobblestone" or "bag of peas" texture) localized predominantly to the upper outer quadrants. Associated with cyclical premenstrual mastalgia and swelling that characteristically peaks during the late luteal phase (several days before menses) and dramatically regresses following menstrual onset.
• Clinical Management:
  • Reassurance that fibrocystic changes without atypia do not confer increased risk of breast carcinoma.
  • Supportive mechanical measures: well-fitting, supportive brassiere (including sports bras during exercise).
  • Lifestyle and medical measures: scheduled NSAIDs (oral ibuprofen or naproxen; topical diclofenac gel), reduction of dietary caffeine and sodium (which may reduce fluid retention), and evening primrose oil. In severe refractory cases, low-dose oral contraceptives or danazol may be considered.

3. Intraductal Papilloma

• Pathophysiology: A benign, localized fibroepithelial polypoid arborization growing within the lumen of a major subareolar lactiferous duct.
• Clinical Significance: The single most common cause of pathologic nipple discharge (accounting for 40% to 50% of cases).
• Clinical Presentation: Typically presents with spontaneous, unilateral, uniductal serosanguinous or frankly bloody nipple discharge in premenopausal or perimenopausal women (ages 30-50). Because the polyp is usually microscopic (<2 to 5 mm) and hidden directly beneath the nipple-areolar complex, a palpable mass is absent in >80% of cases.
• Diagnostic Workup & Management: Diagnostic mammogram and targeted retroareolar high-resolution ultrasound. Ductography (galactography) or ductoscopy may reveal a lumen-filling defect. Definitive management requires surgical referral for microdochectomy (selective terminal duct excision), which provides therapeutic symptom resolution and histological examination to rule out papillary DCIS.

4. Other Benign Mimickers of Carcinoma

• Phyllodes Tumor: A rare fibroepithelial neoplasm characterized by hypercellular stroma arranged in leaf-like projections. Occurs predominantly in women aged 40-50. Presents as a rapidly expanding, large (often >4-5 cm), mobile mass. While most are benign, 10% to 25% are malignant with potential for hematogenous pulmonary metastasis. Treatment requires wide local excision with clear histological margins (>=1 cm); enucleation leads to rapid local recurrence.
• Fat Necrosis: A benign, non-suppurative inflammatory process following blunt breast trauma, seatbelt injury, reduction mammoplasty, biopsy, or radiation therapy. Can produce an irregular, hard, fixed mass with skin retraction, closely mimicking invasive carcinoma clinically and mammographically (lipid cysts, coarse calcifications). Core needle biopsy confirms foamy lipid-laden macrophages, foreign body giant cells, and fat globules.
• Mammary Duct Ectasia: Dilatation of subareolar collecting ducts with periductal inflammation and lipid accumulation, typically in perimenopausal or postmenopausal multiparous women. Presents with thick, sticky, green, white, or brown multi-pore nipple discharge, nipple retraction, and a subareolar mass.

Pathologic vs. Physiologic Nipple Discharge

Nipple discharge accounts for approximately 5% to 10% of outpatient breast complaints. Clinicians must immediately categorize nipple discharge as either physiologic (non-pathologic) or pathologic (suspicious) using distinct clinical features.

               COMPARATIVE MATRIX: NIPPLE DISCHARGE EVALUATION

   Feature                 Physiologic Discharge (Galactorrhea)     Pathologic Nipple Discharge
   ═══════════════════════════════════════════════════════════════════════════════════════════════════
   Laterality              Bilateral (both breasts)                 Unilateral (strictly one breast)

   Spontaneity             Non-spontaneous (requires manual         Spontaneous (discharges onto clothing/bra
                           expression or mechanical stimulation)    without any physical touch)

   Ductal Orifices         Multiductal (emanates from multiple       Uniductal (emanates consistently from a
                           duct pores across the nipple)            single isolated duct pore)

   Fluid Color / Quality   Milky (white), clear, yellow, straw-     Bloody (frankly red), serosanguinous
                           colored, dark green, or brownish         (pink/orange), or clear/watery ("serous")

   Palpable Abnormality    No associated discrete breast mass       Frequently associated with a discrete
                                                                    palpable lump or focal thickening

   Patient Demographics    Reproductive-age females; non-pregnant   Postmenopausal women or MEN
                           or postpartum females                    (ANY discharge in a male is suspicious)

   Underlying Etiology     Endocrine dysfunction (prolactinoma,      Intraductal papilloma (~45%), duct ectasia,
                           hypothyroidism), medication adverse      Ductal Carcinoma In Situ (DCIS ~10-15%),
                           effects, chest wall stimulation          Invasive Ductal Carcinoma
   ═══════════════════════════════════════════════════════════════════════════════════════════════════

Workup of Physiologic Nipple Discharge (Galactorrhea)

True galactorrhea is the inappropriate non-puerperal discharge of milky fluid from multiple ducts bilaterally. It is driven by systemic neuroendocrine mechanisms rather than primary breast parenchymal lesions:

1. Urine or Serum Human Chorionic Gonadotropin (hCG): Mandatory initial test to exclude occult pregnancy.
2. Serum Prolactin Level: Drawn in a fasting, non-stressed state (avoid breast exam or sexual intercourse for 24 hours prior, as tactile nipple stimulation triggers prolactin release).
   • If serum prolactin is significantly elevated (>100 to 200 ng/mL), obtain a Contrast-Enhanced Pituitary MRI to identify a prolactin-secreting pituitary microadenoma (<10 mm) or macroadenoma (>=10 mm).
3. Serum Thyroid-Stimulating Hormone (TSH): Primary hypothyroidism causes compensatory elevation of hypothalamic Thyrotropin-Releasing Hormone (TRH). TRH directly stimulates anterior pituitary lactotrophs, producing hyperprolactinemia and galactorrhea. Correcting hypothyroidism with levothyroxine completely resolves the discharge.
4. Medication History (Dopamine Blockade): Dopamine is the primary physiologic inhibitor of pituitary prolactin secretion via hypothalamic tuberoinfundibular pathways. Any agent blocking dopamine D2 receptors causes hyperprolactinemia:
   • Antipsychotics: First-generation neuroleptics (haloperidol, fluphenazine) and second-generation agents (notably risperidone and paliperidone);
   • Prokinetic / Antiemetic Agents: Metoclopramide and domperidone;
   • Antidepressants: SSRIs, SNRIs, and Tricyclic Antidepressants (TCAs);
   • Antihypertensives: Methyldopa, verapamil, and reserpine.
5. Renal Function (BUN / Serum Creatinine): Chronic kidney disease reduces the clearance of circulating prolactin.

Workup of Pathologic Nipple Discharge

Any discharge meeting pathologic criteria (unilateral, spontaneous, bloody/serosanguinous, uniductal) requires aggressive investigation to rule out malignancy:

• Diagnostic Breast Imaging: Diagnostic bilateral mammogram (including retroareolar magnification views) AND targeted high-resolution subareolar ultrasound to identify intraductal lesions, calcifications, or masses.
• Surgical Referral: Mandatory referral for surgical duct exploration and terminal duct excision (microdochectomy). Removing the involved duct system resolves the discharge and provides definitive histologic diagnosis.
• Diagnostic Pitfall: Nipple discharge cytology (smearing fluid on a slide) has an unacceptably high false-negative rate (>50%) and should NOT be used to exclude malignancy.

Infectious & Inflammatory Breast Disorders

1. Puerperal (Lactational) Mastitis

• Epidemiology: Occurs in approximately 10% to 20% of lactating women, most frequently during the first 6 to 12 weeks postpartum or during abrupt weaning transitions.
• Pathophysiology: Milk stasis is the primary initiating event (incomplete emptying, skipped feedings, poor infant latch, or blocked lactiferous ducts). Stagnant milk provides a rich culture medium. Disrupted epithelial integrity from sore, cracked, or traumatized nipples permits retrograde entry of maternal skin flora or infant nasopharyngeal flora.
• Microbiology: Staphylococcus aureus (both Methicillin-Sensitive [MSSA] and Methicillin-Resistant [MRSA]) is responsible for >75% of cases. Less common organisms include Streptococcus pyogenes (Group A Strep), Streptococcus agalactiae (Group B Strep), and coagulase-negative staphylococci.
• Clinical Presentation: Sudden onset of unilateral focal breast erythema, intense localized tenderness, swelling, induration, accompanied by systemic manifestations: high fever (>38.3°C [101°F]), shaking chills, tachycardia, myalgias, and severe fatigue.

                  ANTIMICROBIAL REGIMENS FOR PUERPERAL MASTITIS

   Clinical Category           Preferred Guideline Antibiotic Regimen      Dosage & Duration
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Outpatient, MSSA            Dicloxacillin                               500 mg PO QID x 10-14 days
   (Standard First-Line)       OR Cephalexin                               500 mg PO QID x 10-14 days

   Penicillin-Allergic         Clindamycin                                 300 mg PO QID x 10-14 days
   (Mild to Severe)            

   Suspected MRSA              Trimethoprim-Sulfamethoxazole (TMP-SMX)*    1 to 2 DS tablets PO BID x 10-14 days
   OR Failed First-Line        OR Clindamycin                              300-450 mg PO QID x 10-14 days
   ═════════════════════════════════════════════════════════════════════════════════════════════
   *SAFETY CAUTION: Avoid TMP-SMX in mothers breastfeeding healthy full-term infants younger than
   2 months or infants with hyperbilirubinemia / G6PD deficiency due to risk of kernicterus.

[!IMPORTANT] CRITICAL CLINICAL PEARL: PRESERVE AND CONTINUE BREASTFEEDING The single most common management error by primary care clinicians is advising an infected mother to cease breastfeeding. Ceasing lactation abruptly dramatically worsens milk stasis, accelerating the development of a frank breast abscess.

Mothers MUST be strongly encouraged to CONTINUE frequent breastfeeding or pumping every 2 to 3 hours. Nursing should begin on the affected breast to ensure complete emptying. Ingesting milk from a mother with mastitis poses NO danger to a healthy infant, as maternal gastric acid and digestive enzymes rapidly neutralize the bacteria. If pain prevents direct latching, the mother must pump the affected breast and nurse from the unaffected side.

2. Breast Abscess

• Pathophysiology: A localized collection of purulent exudate within the breast stroma. It arises as a direct complication in 3% to 11% of acute mastitis cases due to delayed antibiotic initiation or incomplete bacterial clearance.
• Clinical Signs & Red Flags:
  • Persistent high fevers, leukocytosis, and systemic toxicity after 48 to 72 hours of appropriate oral antibiotic therapy;
  • A distinct, palpable, exquisitely tender, fluctuant mass or area of induration with overlying tense, shiny, erythematous skin.
• Diagnostic Confirmation: Urgent Targeted Bedside Breast Ultrasound. Ultrasound readily distinguishes a solid phlegmon (hyperechoic tissue edema) from an abscess cavity, seen as an anechoic or hypoechoic fluid collection with thick, irregular walls, internal debris/septations, and posterior acoustic enhancement.
• Management:
  • Ultrasound-Guided Percutaneous Needle Aspiration: The first-line intervention for abscesses <5 cm. Aspirated pus is sent for Gram stain, culture, and antimicrobial susceptibility. Aspiration is repeated every 2 to 3 days until fluid no longer re-accumulates.
  • Percutaneous Catheter Drainage: For larger cavities (>=3 to 5 cm) or when serial aspiration fails; a small pigtail catheter is placed for continuous drainage.
  • Surgical Incision & Drainage (I&D): Reserved for very large multilocular abscesses, necrotic overlying skin, or failed percutaneous drainage. Surgical drainage carries higher risks of milk fistula formation and cosmetic scarring.
  • Lactation Guidance: The mother should continue breastfeeding from the contralateral unaffected breast. The affected breast must be regularly pumped and the milk discarded until drainage ceases, after which direct nursing may resume.

3. Inflammatory Breast Cancer (IBC): The Lethal Mimicker

[!CAUTION] BOARD EXAM ALERT: INFLAMMATORY BREAST CANCER (IBC) Inflammatory breast cancer is the most aggressive and lethal form of primary breast malignancy (representing 1-2% of all breast cancers but accounting for 10% of breast cancer mortality). It is notorious on board examinations because it presents identically to acute mastitis.

• Clinical Presentation:
  • Rapid onset (typically <3 months) of diffuse erythema, warmth, severe breast enlargement, tenderness, and marked skin edema.
  • "Peau d'orange" (Orange Peel Skin): Thickened, dimpled, indurated skin resulting from cutaneous lymphatic obstruction.
  • Erythema must involve at least one-third (>=33%) of the entire breast skin surface.
  • A discrete underlying palpable mass is ABSENT in over 50% to 70% of cases because the tumor grows in a diffuse sheet-like permeation pattern.
  • Ipsilateral axillary and supraclavicular lymphadenopathy is present in up to 75% of patients at initial presentation.
• Pathophysiologic Mechanism: Neoplastic tumor emboli invade and plug the superficial dermal lymphatic capillaries, obstructing lymphatic drainage and causing severe interstitial lymphedema and reactive hyperemia.
• The Critical Clinical Red Flags:
  • Any woman presenting with apparent mastitis who is non-lactating or postmenopausal;
  • Any lactating woman treated for presumed mastitis who fails to demonstrate rapid clinical improvement within 7 to 10 days of guideline-directed antibiotic therapy.
• Definitive Diagnostic Workup:
  • Immediate Diagnostic Bilateral Mammography and Targeted Ultrasound (demonstrates skin thickening >2 mm, diffuse stromal coarsening, and suspicious regional lymph nodes);
  • Full-Thickness Skin Punch Biopsy (>=4 mm): Performed directly over the most indurated, erythematous area of peau d'orange skin. Demonstrating neoplastic carcinoma emboli within the dermal lymphatic channels is pathognomonic and confirms the diagnosis (T4d staging);
  • Core needle biopsy of any underlying breast parenchymal mass or abnormal axillary lymph nodes.